Parkinson’s disease (PD) is identified as the most common neurodegenerative disorder of the central nervous system. Around 8.5 million individuals suffer from PD globally. Neuroinflammation triggers the activation of microglia, resulting in the release of numerous proinflammatory mediators. A major modulator of immune response in Parkinsonism is the kynurenine pathway (KP), probably linked to neurotoxic and inflammatory processes. Two types of compounds are produced by this pathway that act as neurotoxic and neuroprotective. Among these, kynurenic acid released by astrocytes acts as neuroprotective, and quinolinic acid released by microglia acts as neurotoxic by various mechanisms. Previous studies have shown that modulation of enzymes in this pathway can be a therapeutic approach for treating PD. Studies were performed to determine the effect of various drug treatments in inhibiting the enzymes of KP and preventing neurodegeneration. Pharmacological modulators of the KP enzymes will likely be a novel therapeutic approach for PD, and some of the KP metabolites may serve as predictive biomarkers.
SantamariaALa CruzVKonigsbergM.Kynurenine pathway and disease: an overview. CNS Neurol Disord Drug Targets. 2008;6(6):398-410.
2.
BraidyNGuilleminGJGrantR.Effects of kynurenine pathway inhibition on NAD+ metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res. 2011;4(1):29-37.
3.
StoneTW.Endogenous neurotoxins from tryptophan. Toxicon. 2001;39(1):61-73.
ZádorFJocaSNagy-GróczG, et al. Pro-inflammatory cytokines: potential links between the endocannabinoid system and the kynurenine pathway in depression. Int J Mol Sci. 2021;22(11):5903.
6.
ChenPGengX.Research progress on the kynurenine pathway in the prevention and treatment of Parkinson’s disease. J Enzyme Inhib Med Chem. 2023;38(1):2225800.
7.
O’ConnorJCAndréCWangY, et al. Interferon-γ and tumor necrosis factor-α mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci. 2009;29(13):4200-4209.
8.
StoneTWPerkinsMN.Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981;72(4):411-412.
9.
LapinIP.Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J Neural Transm. 1978;42:37-43.
10.
MaddisonDCGiorginiF.The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol. 2015;40:134-141.
11.
BraidyNGrantRAdamsSBrewBJGuilleminGJ.Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77-86.
12.
VazquezSGarnerBSheilMMTruscottRJW. Characterisation of the major autoxidation products of 3-hydroxykynurenine under physiological conditions. Free Radic Res. 2000;32(1):11-23.
13.
KrauseDSuhHSTarassishinL, et al. The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1. Am J Pathol. 2011;179(3):1360-1372.
14.
SchuckPFToninAda Costa FerreiraG, et al. Kynurenines impair energy metabolism in rat cerebral cortex. Cell Mol Neurobiol. 2007;27:147-160.
15.
LiJSHanQFangJRizziMJamesAALiJ.Biochemical mechanisms leading to tryptophan 2,3-dioxygenase activation. Arch Insect Biochem Physiol. 2007;64(2):74-87.
16.
WalkerAKBudacDPBisulcoS, et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology. 2013;38(9):1609-1616.
17.
KonanKVTaylorMW.Importance of the two interferon-stimulated response element (ISRE) sequences in the regulation of the human indoleamine 2,3-dioxygenase gene. J Biol Chem. 1996;271(32):19140-19145.
18.
CampbellBMCharychELeeAWMöllerT.Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12.
19.
ConnorTJStarrNO’SullivanJBHarkinA.Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-γ?Neurosci Lett. 2008;441(1):29-34.
20.
GálEMShermanAD.L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5:223-239.
21.
GuilleminGJSmithDGSmytheGAArmatiPJBrewGJ.Expression of the kynurenine pathway enzymes in human microglia and macrophages. In: AllegriGCostaCVLRagazziE, et al, eds. Developments in Tryptophan and Serotonin Metabolism. Springer; 2003:105-112.
22.
GuilleminGJKerrSJSmytheGA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78(4):842-853.
23.
FukuiSSchwarczRRapoportSITakadaYSmithQR.Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56(6):2007-2017.
24.
CaudleWMZhangJ.Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol. 2009;220(2):230-233.
25.
SzabóNKincsesZTToldiJVécseiL.Altered tryptophan metabolism in Parkinson’s disease: a possible novel therapeutic approach. J Neurol Sci. 2011;310(1-2):256-260.
26.
ZádoriDKlivényiPPlangárIToldiJVécseiL.Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med. 2011;15(4):701-717.
27.
OgawaTMatsonWRBealMF, et al. Kynurenine pathway abnormalities in Parkinson’s disease. Neurology. 1992;42(9):1702.
28.
HartaiZKlivenyiPJanakyTPenkeBDuxLVecseiL.Kynurenine metabolism in plasma and in red blood cells in Parkinson’s disease. J Neurol Sci. 2005;239(1):31-35.
29.
LeeKSLeeHJNohYH, et al. Kynurenic acid attenuates MPP+-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway. Eur J Cell Biol. 2008;87(6):389-397.
30.
GuidettiPBatesGPGrahamRK, et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis. 2006;23(1):190-197.
31.
ZádoriDKlivényiPToldiJFülöpFVécseiL.Kynurenines in Parkinson’s disease: therapeutic perspectives. J Neural Transm. 2012;119:275-283.
32.
NémethHToldiJVécseiL.Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies. J Neural Transm Suppl. 2006;70:285-304.
33.
VamosEVorosKZadoriDVecseiLKlivenyiP.Neuroprotective effects of probenecid in a transgenic animal model of Huntington’s disease. J Neural Transm. 2009;116:1079-1086.
34.
ChenYGuilleminGJ.Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res. 2009;2:1-19.
35.
SchwarczRKöhlerC.Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci Lett. 1983;38(1):85-90.
36.
SinghSKumarVVashishtK, et al. Role of genetic polymorphisms of CYP1A1, CYP3A5, CYP2C9, CYP2D6, and PON1 in the modulation of DNA damage in workers occupationally exposed to organophosphate pesticides. Toxicol Appl Pharmacol. 2011;257(1):84-92.
37.
AguileraPChánez-CárdenasMEFloriano-SánchezE, et al. Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington’s disease. Neurotoxicology. 2007;28(6):1200-1207.
38.
GuilleminGJCroitoru-LamouryJDormontDArmatiPJBrewBJ.Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes. Glia. 2003;41(4):371-381.
39.
WilsonENUmansJSwarovskiMS, et al. Parkinson’s disease is characterized by vitamin B6-dependent inflammatory kynurenine pathway dysfunction. NPJ Parkinsons Dis. 2025;11(1):96.
40.
SorgdragerFJHVermeirenYVan FaassenM, et al. Age- and disease-specific changes of the kynurenine pathway in Parkinson’s and Alzheimer’s disease. J Neurochem. 2019;151(5):656-668.
41.
StipekSStastnyFPlatenikJCrkovskaJZimaT.The effect of quinolinate on rat brain lipid peroxidation is dependent on iron. Neurochem Int. 1997;30(2):233-237.
42.
GodaKKishimotoRShimizuSHamaneYUedaM.Quinolinic acid and active oxygens: possible contribution of active oxygens during cell death in the brain. Adv Exp Med Biol. 1996;398:247-254.
43.
BraidyNGrantRAdamsSGuilleminGJ.Neuroprotective effects of naturally occurring polyphenols on quinolinic acid-induced excitotoxicity in human neurons. FEBS J. 2010;277(2):368-382.
44.
Pérez-DeLaCruzVElinos-CalderónDCarrillo-MoraP, et al. Time-course correlation of early toxic events in three models of striatal damage: modulation by proteases inhibition. Neurochem Int. 2010;56(6-7):834-842.
45.
Rodríguez-MartínezECamachoAMaldonadoPD, et al. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res. 2000;858(2):436-439.
46.
Pérez-DeLaCruzVGonzález-CortésCGalván-ArzateS, et al. Excitotoxic brain damage involves early peroxynitrite formation in a model of Huntington’s disease in rats: protective role of iron porphyrinate 5,10,15,20-tetrakis (4-sulfonatophenyl)porphyrinate iron (III). Neuroscience. 2005;135(2):463-474.
47.
ChenYBrewBJGuilleminGJ.Characterization of the kynurenine pathway in NSC-34 cell line: implications for amyotrophic lateral sclerosis. J Neurochem. 2011;118(5):816-825.
48.
DairamAChettyPDayaS.Non-steroidal anti-inflammatory agents, tolmetin and sulindac, attenuate oxidative stress in rat brain homogenate and reduce quinolinic acid-induced neurodegeneration in rat hippocampal neurons. Metab Brain Dis. 2006;21:211-223.
49.
DairamAMüllerACDayaS.Non-steroidal anti-inflammatory agents, tolmetin and sulindac attenuate quinolinic acid (QA)-induced oxidative stress in primary hippocampal neurons and reduce QA-induced spatial reference memory deficits in male Wistar rats. Life Sci. 2007;80(15):1431-1438.
50.
SantamaríaASantamaríaDDíaz-MuñozMEspinoza-GonzálezVRíosC.Effects of N omega-nitro-L-arginine and L-arginine on quinolinic acid-induced lipid peroxidation. Toxicol Lett. 1997;93(2-3):117-124.
51.
SadeghniaHRKamkarMAssadpourEBoroushakiMTGhorbaniA.Protective effect of safranal, a constituent of Crocus sativus, on quinolinic acid-induced oxidative damage in rat hippocampus. Iran J Basic Med Sci. 2013;16(1):73.
52.
BehanWMHMcDonaldMDarlingtonLGStoneTW. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol. 1999;128(8):1754-1760.
53.
MayaSPrakashTGoliD.Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis. Neurotoxicology. 2018;68:1-12.
54.
LoganathanCThayumanavanP.Asiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment. Metab Brain Dis. 2018;33(1):151-159.
55.
RayeganSDehpourARSharifiAM.Studying neuroprotective effect of Atorvastatin as a small molecule drug on high glucose-induced neurotoxicity in undifferentiated PC12 cells: role of NADPH oxidase. Metab Brain Dis. 2017;32(1):41-49.
56.
RyuJKChoiHBMcLarnonJG.Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington’s disease. Neuroscience. 2006;141(4):1835-1848.
57.
BraidyNGrantR.Kynurenine pathway metabolism and neuroinflammatory disease. Neural Regen Res. 2017;12(1):39-42.
58.
SchwarczRStoneTW.The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology. 2017;112:237-247.
59.
GuilleminGJSmithDGKerrSJ, et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep. 2000;5(2-3):108-111.
60.
ZhouQShengM.NMDA receptors in nervous system diseases. Neuropharmacology. 2013;74:69-75.
61.
JiangYMaHWangX, et al. Protective effect of the α7 nicotinic receptor agonist PNU-282987 on dopaminergic neurons against 6-hydroxydopamine, regulating anti-neuroinflammatory and the immune balance pathways in rat. Front Aging Neurosci. 2021;12:606927.
62.
Knyihár-CsillikECsillikBPákáskiM, et al. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience. 2004;126(4):899-914.
63.
LeWittPALiJLuM, et al. 3-Hydroxykynurenine and other Parkinson’s disease biomarkers discovered by metabolomic analysis. Mov Disord. 2013;28(12):1653-1660.
64.
Silva-AdayaDPérez-DeLaCruzVVilleda-HernándezJ, et al. Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol. 2011;33(2):303-312.
65.
LovelaceMDVarneyBSundaramG, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology. 2017;112:373-388.
66.
SalinasJBeiserAHimaliJJ, et al. Associations between social relationship measures, serum brain-derived neurotrophic factor, and risk of stroke and dementia. Alzheimers Dement. 2017;3(2):229-237.
67.
WidnellK.Pathophysiology of motor fluctuations in Parkinson’s disease. Mov Disord. 2005;20(S11):S17-S22.
68.
DifazioMCHollingsworthZYoungABPenneyJBJr.Glutamate receptors in the substantia nigra of Parkinson’s disease brains. Neurology. 1992;42(2):402.
69.
KikuchiSKimSU.Glutamate neurotoxicity in mesencephalic dopaminergic neurons in culture. J Neurosci Res. 1993;36(5):558-569.
70.
ConnopBPBoegmanRJJhamandasKBeningerRJ.Excitotoxic action of NMDA agonists on nigrostriatal dopaminergic neurons: modulation by inhibition of nitric oxide synthesis. Brain Res. 1995;676(1):124-132.
71.
WuHQLeeSCSchwarczR.Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. Eur J Pharmacol. 2000;390(3):267-274.
72.
StoneTW.Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci. 2000;21(4):149-154.
73.
ZádoriDNyiriGSzonyiA, et al. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington’s disease. J Neural Transm. 2011;118:865-875.
74.
MartosDLőrincziBSzatmáriIVécseiLTanakaM.The impact of C-3 side chain modifications on kynurenic acid: a behavioral analysis of its analogs in the motor domain. Int J Mol Sci. 2024;25(6):3394.
75.
BalogEJeneiGBerkóAM, et al. Age-dependent changes in NMDA-induced excitotoxicity and neuromodulatory effects of kynurenic acid and its analogue in mouse brain slices. Neurosci Lett. 2025;854:138220.
76.
ChenCMHuangCYLaiCHChenYCHwangYTLinCY.Neuroprotection effects of kynurenic acid-loaded micelles for the Parkinson’s disease models. J Liposome Res. 2024;34(4):593-604.
77.
FüvesiJSomlaiCNémethH, et al. Comparative study on the effects of kynurenic acid and glucosamine-kynurenic acid. Pharmacol Biochem Behav. 2004;77(1):95-102.
78.
YuCPPanZZLuoDY.TDO as a therapeutic target in brain diseases. Metab Brain Dis. 2016;31:737-747.
79.
YentzSSmithD.Indoleamine 2,3-dioxygenase (IDO) inhibition as a strategy to augment cancer immunotherapy. BioDrugs. 2018;32(4):311-317.
80.
LöbSKönigsrainerAZiekerD, et al. IDO1 and IDO2 are expressed in human tumors: levo-but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother. 2009;58:153-157.
81.
QinYWangNZhangXHanXZhaiXLuY.IDO and TDO as a potential therapeutic target in different types of depression. Metab Brain Dis. 2018;33:1787-1800.
82.
BallHJJusofFFBakmiwewaSMHuntNHYuasaHJ.Tryptophan-catabolizing enzymes—party of three. Front Immunol. 2014;5:485.
83.
van der GootATZhuWVázquez-ManriqueRP, et al. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation. Proc Natl Acad Sci U S A. 2012;109(37):14912-14917.
84.
Perez-PardoPGrobbenYWillemsen-SeegersN, et al. Pharmacological validation of TDO as a target for Parkinson’s disease. FEBS J. 2021;288(14):4311-4331.
85.
WoodlingNSColasDWangQ, et al. Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer’s disease model mice. Brain. 2016;139(7):2063-2081.
86.
SodhiRKBansalYSinghR, et al. IDO-1 inhibition protects against neuroinflammation, oxidative stress and mitochondrial dysfunction in 6-OHDA induced murine model of Parkinson’s disease. Neurotoxicology. 2021;84:184-197.
87.
DuanZShiLHeZNTKuangCHanTYangQ.The protective effect of IDO1 inhibition in Aβ-treated neurons and APP/PS1 mice. Am J Alzheimers Dis Other Demen. 2023;38:15333175231214860.
88.
DolušićELarrieuPMoineauxL, et al. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl) indoles as potential anticancer immunomodulators. J Med Chem. 2011;54(15):5320-5334.
89.
FertanEStoverKRJBrantMG, et al. Effects of the novel IDO inhibitor DWG-1036 on the behavior of male and female 3xTg-AD mice. Front Pharmacol. 2019;10:1-16.
90.
ZingerABarciaCHerreroMTGuilleminGJ.The involvement of neuroinflammation and kynurenine pathway in Parkinson’s disease. Parkinsons Dis. 2011;2011:716859.
91.
Crozier-ReabeKRPhillipsRSMoranGR.Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide. Biochemistry. 2008;47(47):12420-12433.
92.
ChiarugiACarpenedoRMoroniF.Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J Neurochem. 1996;67(2):692-698.
93.
SpecialeCWuHQCiniMMarconiMVarasiMSchwarczR.(R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. Eur J Pharmacol. 1996;315(3):263-267.
94.
PhillipsRSAndersonADGentryHGGünerOFBowenJP.Substrate and inhibitor specificity of kynurenine monooxygenase fromCytophaga hutchinsonii. Bioorg Med Chem Lett. 2017;27(8):1705-1708.
95.
RöverSCesuraAMHugueninPKettlerRSzenteA.Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J Med Chem. 1997;40(26):4378-4385.
96.
ZwillingDHuangSYSathyasaikumarKV, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145(6):863-874.
97.
HutchinsonJPRowlandPTaylorMRD, et al. Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenine-3-monooxygenase. Nat Commun. 2017;8(1):15827.
98.
ShaveSMcGuireKPhamNTMoleDJWebsterSPAuerM.Diclofenac identified as a kynurenine 3-monooxygenase binder and inhibitor by molecular similarity techniques. ACS Omega. 2018;3(3):2564-2568.
99.
RebaiRCarmena-BargueñoMToumiME, et al. Identification of potent inhibitors of kynurenine-3-monooxygenase from natural products: in silico and in vitro approaches. Heliyon. 2024;10(9):e30287.
